Best practices in preclinical algesiometry (pain behaviour testing) have shifted over the past
decade as a result of technological advancements, the continued dearth of translational …

Objective To summarize the pharmacology of the calcitonin peptide family of receptors and
explore their relationship to migraine and current migraine therapies. Background …

Introduction Since calcitonin gene-related peptide (CGRP) plays an important role in the
pathophysiology of migraine via the activation of the trigeminovascular system, the newest …

Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide
(CGRP) belong to a new generation of therapeutics that are effective in the prevention of …

Why can we still not translate preclinical research to clinical treatments for acute strokes?
Despite> 1000 successful preclinical studies, drugs, and concepts for acute stroke, only two …

Migraine pain is characterized by an intense, throbbing pain in the head area and
possesses complex pathological and physiological origins. Among the various factors …

Chronic pain remains a major problem worldwide, despite the availability of various non-
pharmacological and pharmacological treatment options. Therefore, new analgesics with …

Migraine is a complex neurological disorder with a high disability rate. Although the
precipitating factors of migraine remain unclear, previous studies suggest that when there is …

Receptor activity-modifying proteins (RAMPs) interact with G-protein-coupled receptors
(GPCRs) to modify their functions, imparting significant implications upon their physiological …

Recently developed anti-migraine therapeutics targeting calcitonin gene-related peptide
(CGRP) signaling are effective, though their sites of activity remain elusive. Notably, the …